SCHEMBL1743906

SCHEMBL1743906

COC(=O)CCCCCCCCCOc1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
PRKCA P17252 1/20 0.45
HTT P42858 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
LTA4H P09960 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
HDAC8 Q9BY41 4/20 0.44
HDAC3 O15379 3/20 0.44
HDAC4 P56524 3/20 0.44
HDAC1 Q13547 3/20 0.44
HDAC7 Q8WUI4 3/20 0.44
HDAC2 Q92769 3/20 0.44
HDAC10 Q969S8 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558993 1.00 MAPT (0.53) MAPTGAARAB9AL3MBTL1PRKCA
SCHEMBL26092045 1.00 MAPT (0.53) MAPTGAARAB9AL3MBTL1PRKCA
SCHEMBL1363883 0.95 PPARA (0.51) MAPTGAARAB9AHTTLTA4H
SCHEMBL558015 0.95 MAPT (0.48) MAPTGAARAB9AL3MBTL1PRKCA
SCHEMBL4262672 0.87 MAPT (0.70) MAPTGAARAB9AL3MBTL1HTT
SCHEMBL2921102 0.86 PDE3B (0.41) MAPTGAAHDAC8
SCHEMBL4540684 0.86 PPARA (0.58) MAPTGAAL3MBTL1TP53TSHR
SCHEMBL4538607 0.86 PPARA (0.58) MAPTGAAL3MBTL1TP53TSHR
SCHEMBL20567660 0.86 PPARA (0.58) MAPTGAAL3MBTL1TP53TSHR
SCHEMBL1745096 0.86 PPARA (0.58) MAPTGAAL3MBTL1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023069994-A1 IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-27 WO disclosed
EP-2386572-B1 Insulin derivative NOVO NORDISK AS (DK) 2015-07-08 EP disclosed
US-8933021-B2 Insulin derivative NOVO NORDISK A/S (DK) 2015-01-13 US disclosed
EP-2015770-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2012-09-26 EP disclosed
EP-2386572-A1 Insulin derivative Novo Nordisk A/S (DK) 2011-11-16 EP disclosed
US-8039101-B2 Radio-opaque dental prosthetic member Societe de Recherches Techniques Dentaires-R.T.D. (FR) 2011-10-18 US disclosed
US-20090239785-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-09-24 US disclosed
EP-2015770-A2 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-01-21 EP disclosed
WO-2007128817-A2 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239785-A1 Insulin Derivative IAPP, INSR, GPR119 MAPT 3865/4885GAA 444/4885RAB9A 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.